Evidence map›Paper›PMID 25680758›Full record

ReviewVision research2015

Photochemical approaches to vision restoration.

Russell N Van Gelder

Open access · greenAbstract readReview
In one paragraph

Review in Vision research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Clinical and Molecular Aspects of C2orf71/PCARE in Retinal Diseases.International journal of molecular sciences · 2023
    Review
  6. New tricks and emerging applications from contemporary azobenzene research.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022
    Article
  7. Non-Therapeutic Laser Retinal Injury.International journal of ophthalmic research · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Russell N Van GelderDepartment of Ophthalmology, University of Washington School of Medicine, United States; Department of Pathology, University of Washington School of Medicine, United States; Department of Biological Structure, University of Washington School of Medicine, United States. Electronic address: russvg@uw.edu.
University of Washington · US

Funding

NDC for the Optical Control of Biological FunctionPN2EY018241 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI ISACOFF, EHUD · 2006 to 2015
$37.5M
Vision Research CoreP30EY001730 · NEI · UNIVERSITY OF WASHINGTON · PI JAMES Bryant HURLEY · 1985 to 2026
$23.5M
Photoswitchable channel blockers for treatment of blindnessR24EY023937 · NEI · UNIVERSITY OF WASHINGTON · PI VAN GELDER, RUSSELL N. · 2014 to 2018
$6.1M
Optical Control of Synaptic Transmission for in Vivo Analysis of Brain Circuits and BehaviorU01NS090527 · NINDS · UNIVERSITY OF CALIFORNIA BERKELEY · PI ISACOFF, EHUD, KRAMER, RICHARD H · 2014 to 2016
$2.4M
NEI NIH HHS P30 EY001730NEI NIH HHS P30 EY01730NEI NIH HHS PN2 EY018241NEI NIH HHS R24 EY023937NINDS NIH HHS U01 NS090527
6 · The paper itself

Abstract

Photoswitches are traditional pharmacologic agonists, antagonists, or channel blockers that are covalently modified with an azobenzene derivative. Azobenzene undergoes wavelength-dependent isomerization between cis and trans conformation. For some photoswitches, only one of these configurations is biologically active, resulting in light-dependent activation or inhibition of function. Photoswitches that feature a quaternary ammonium coupled to the azobenzene moiety cause light-dependent neuronal depolarization due to blockage of voltage-gated potassium channels. Two photoswitch strategies have been pursued. In the one-component strategy, the photoswitch is applied to native receptors; in the two-component strategy, the photoswitch is combined with virally-mediated expression of a genetically modified receptor, to which the photoswitch may covalently bind. The former approach is simpler but the latter allows precise anatomic targeting of photoswitch activity. Acrylamide-azobenzene-quaternary ammonium (AAQ) is the prototypical first-generation one-component photoswitch. When applied to retinas with outer retinal degeneration, ganglion cell firing occurs in response to blue light, and is abrogated by green light. In vivo, AAQ restored pupillary light responses and behavioral light responses in blind animals. DENAQ is a prototypical second generation one-component photoswitch. It features spontaneous thermal relaxation so cell firing ceases in dark, and features a red-shifted activation spectrum. Interestingly, DENAQ only photoswitches in retinas with outer retinal degeneration. MAG is a photoswitched glutamate analog which covalently binds to a modified ionotropic glutamate receptor, LiGluR. When applied together, MAG and LiGluR also rescue physiologic and behavioral light responses in blind mice. Together, photoswitch compounds offer a potentially useful approach to restoration of vision in outer retinal degeneration.

Indexed as

AnimalsAzo CompoundsBlindnessHumansLightMicePhotosensitizing AgentsRetinaRetinal DegenerationRetinal Ganglion CellsAzo CompoundsPhotosensitizing AgentsPharmacologyPhotoswitchRetinal degenerationRetinal ganglion cells

Identifiers

PMID25680758
PMCPMC4444397
OpenAlexW2092170412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.